Bill Current

Bill Current joined Apexian in December 2014. He brings significant regulatory, discovery, and development experience in the pharmaceutical and biotechnology industry.

Prior to joining Eli Lilly and Company as a Senior Research Scientist, Bill was a Professor at Auburn University. At Lilly, he was Team Leader for numerous infectious disease research programs and Chairman of the Antifungal and Opportunistic Pathogens Research Group. He also served as Senior Regulatory Advisor (Director) and the Regulatory Coordinator responsible for the strategy and leadership of Global Regulatory Affairs sub-teams that provided regulatory oversight for more than 25 drug and device development teams and for more than 30 marketed drugs.

He has served as VP of Regulatory Affairs for Targanta Therapeutics (anti-infective biotech), and BioCritica (critical care biotech); as Acting Vice President or Regulatory Affairs for Malinta (formerly RibeX, anti-infective biotech); and as a Senior Regulatory Consultant for the Autoimmune Platform of Lilly (three Phase 3 teams).

Bill has served on the editorial boards of four refereed journals and has been a reviewer for another 10 refereed journals. He served on numerous NIH and USDA Study Sections, Review Committees, and Working Groups. He has authored or co-authored more than 300 publications that include 81 refereed journal articles, 37 invited publications and book chapters, 70 papers presented at meeting, and 93 invited lectures, symposium papers, and workshops. Bill received a B.S. in Biology from New Mexico State University, an M.S in Parasitology from Eastern Washington State University, and a Ph.D. in Life Sciences from The University of Nebraska.